Clinical pharmacology of the combination of ACE inhibitors and calcium antagonists: benefits of the perindopril arginine and amlodipine combination

Clinical pharmacology of the combination of ACE inhibitors and calcium antagonists: benefits of the perindopril arginine and amlodipine combination

The paper reviews the modern evidence on mechanisms of action and clinical effectiveness of two cardiovascular medication classes – angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists (CA), used for the treatment of patients with arterial hypertension (AH) and coronary heart disea...

Szczegółowa specyfikacja

Opis bibliograficzny
1. autor:	M. V. Leonova
Format:	Artykuł
Język:	Russian
Wydane:	«SILICEA-POLIGRAF» LLC 1970-01-01
Seria:	Кардиоваскулярная терапия и профилактика
Hasła przedmiotowe:	renin-angiotensin system endothelial dysfunction ace inhibitors calcium antagonists arterial hypertension coronary heart disease
Dostęp online:	https://cardiovascular.elpub.ru/jour/article/view/2181

Podobne zapisy

MECHANISMS OF COMBINED ACTION OF ACE INHIBITORS AND CALCIUM ANTAGONISTS IN ARTERIAL HYPERTENSION
od: E. I. Astashkin, i wsp.
Wydane: (2013-06-01)

Efficacy of a fixed-dose combination of perindopril and amlodipine in the treatment of hypertensive patients. A clinical case
od: N G Poteshkina, i wsp.
Wydane: (2014-12-01)

Angiotensin II type 1 receptor antagonists and ACE inhibitors in the regulation of hemodynamics and renin-angiotensin-aldosterone system activity: focus on the organ protection
od: M. L. Maksimov, i wsp.
Wydane: (2010-04-01)

Vitamin D improves hepatic alterations in ACE1 and ACE2 expression in experimentally induced metabolic syndrome
od: Sara Mohater, i wsp.
Wydane: (2023-09-01)

Age-related reduction in brain ACE-2 is not exacerbated by Alzheimer’s disease pathology in mouse models of Alzheimer’s disease
od: Robert MacLachlan, i wsp.
Wydane: (2023-01-01)

Possible combined effect of perindopril and Azilsartan in an experimental model of dementia in rats
od: Yahya M. Alzahrani, i wsp.
Wydane: (2020-05-01)

Biological sex differences in renin angiotensin system enzymes ACE and ACE2 regulate normal tissue response to radiation injury
od: Guru Prasad Sharma, i wsp.
Wydane: (2023-05-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES
od: E. M. Khurs, i wsp.
Wydane: (2016-01-01)

Epilepsy Seizures in Spontaneously Hypertensive Rats After Acoustic Stimulation: Role of Renin–Angiotensin System
od: Christiane Becari, i wsp.
Wydane: (2020-12-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
od: Shuichi Ichikawa, i wsp.
Wydane: (2011-06-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND PROTEINURIA
od: Tanja Kök, i wsp.
Wydane: (2002-03-01)

Placental ACE2 Expression: A Possible Pathogenetic Mechanism for Infantile Hemangiomas
od: Aurora De Marco, i wsp.
Wydane: (2024-07-01)

SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease
od: Nahid Alimoradi, i wsp.
Wydane: (2022-03-01)

Exploring the Link between ACE Insertion/Deletion (I/D) Polymorphism and Uterine Leiomyomas
od: Shirin Shahbazi, i wsp.
Wydane: (2017-03-01)

COMBINED ANTIHYPERTENSIVE THERAPY: ACE INHIBITOR PLUS CALCIUM CHANNEL BLOCKER. NEW ADVANTAGES OF THE KNOWN COMBINATION
od: S. A. Boitsov, i wsp.
Wydane: (2016-01-01)

Reminiscences of Ervin G Erdös
od: Igić Rajko
Wydane: (2019-01-01)

Children With Short Stature Display Reduced ACE2 Expression in Peripheral Blood Mononuclear Cells
od: Federica Tonon, i wsp.
Wydane: (2022-07-01)

AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND CALCIUM ANTAGONIST COMBINATION IN PHARMACOTHERAPY OF ARTERIAL HYPERTENSION
od: L. L. Kirichenko, i wsp.
Wydane: (2014-02-01)

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
od: K. A. Ghyamdzhyan, i wsp.
Wydane: (2022-12-01)

Principles of choice of an angiotensin-converting enzyme inhibitor: Specific features of perindopril
od: T E Morozova, i wsp.
Wydane: (2014-09-01)

The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19
od: Mira Bosso, i wsp.
Wydane: (2020-09-01)

Perindopril arginine: a new ACE inhibitor salt increases therapeutic potential
od: Yu. A. Karpov
Wydane: (2008-12-01)

Predicted Release and Analysis of Novel ACE-I, Renin, and DPP-IV Inhibitory Peptides from Common Oat (Avena sativa) Protein Hydrolysates Using in Silico Analysis
od: Stephen Bleakley, i wsp.
Wydane: (2017-12-01)

Divergence in the activity of the N- and C- catalytic domains of ACE1 - implications for the role of the renin-angiotensin system in Alzheimer’s disease
od: Noura S. AL Mulhim, i wsp.
Wydane: (2019-04-01)

Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I- converting enzyme deletion/deletion genotype
od: E.P. Velloso, i wsp.
Wydane: (2007-04-01)

Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I- converting enzyme deletion/deletion genotype
od: E.P. Velloso, i wsp.

THE PATHOPHYSIOLOGY RELATIONSHIP OF HYPERTENSION AND RENAL HYPERTENSION
od: Akmarawita Kadir
Wydane: (2018-02-01)

Molecular Mimicry of the Viral Spike in the SARS-CoV-2 Vaccine Possibly Triggers Transient Dysregulation of ACE2, Leading to Vascular and Coagulation Dysfunction Similar to SARS-CoV-2 Infection
od: Christian A. Devaux, i wsp.
Wydane: (2023-04-01)

The renin-angiotensin system and its blockers
od: Igić Rajko, i wsp.
Wydane: (2014-01-01)

The ACE2/Angiotensin-(1–7)/Mas Receptor Axis: Pleiotropic Roles in Cancer
od: Juanjuan Xu, i wsp.
Wydane: (2017-05-01)

Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients
od: Ikram Omar Osman, i wsp.
Wydane: (2021-06-01)

Angiotensin-converting-enzyme gene insertion-deletion polymorphism and renin angiotensin aldosterone system activity in different phenotypes of polycystic ovary syndrome
od: Khansa Chaabouni, i wsp.
Wydane: (2024-11-01)

Characterization of angiotensin-converting enzymes 1 and 2 in the soleus and plantaris muscles of rats
od: T. Fernandes, i wsp.
Wydane: (2010-09-01)

Experience of using a fixed-dose combination of perindopril and amlodipine in the clinical practice settings: a real-world opportunity to increase antihypertensive therapy effectiveness
od: O. D. Ostroumova, i wsp.
Wydane: (2013-10-01)

Comparison of angiotensin converting enzyme 1 levels to the grading of knee osteoarthritis
od: Fidelia Elvira Da Costa Rao, i wsp.
Wydane: (2024-06-01)

Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia
od: Daniela-Carmen Ababei, i wsp.
Wydane: (2023-09-01)

IMPROVEMENT OF AMLODIPINE CONTROL EFFICACY OVER HYPERTENSION USING FIXED COMBINATION OF PERINDOPRIL ARGININE AND AMLODIPINE
od: O. N. Kryuchkova, i wsp.
Wydane: (2015-05-01)

Fraxinol attenuates LPS-induced acute lung injury by equilibrating ACE-Ang II-AT1R and ACE2-Ang (1-7)-Mas and inhibiting NLRP3
od: Yan Wu, i wsp.
Wydane: (2022-12-01)

Association between renin‐angiotensin antagonism and COVID‐19–related mortality in patients with essential hypertension: A single center, retrospective cohort study
od: Vijayvardhan Kamalumpundi, i wsp.
Wydane: (2024-09-01)

Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies
od: Murtala Bello Abubakar, i wsp.
Wydane: (2021-05-01)